Peptides for Neuropathy — Evidence Review
Neuropathy is heterogeneous: diabetic peripheral neuropathy, post-traumatic nerve injury, chemotherapy-induced neuropathy, and idiopathic small-fiber neuropathy each have different mechanisms and…
Neuropathy is heterogeneous: diabetic peripheral neuropathy, post-traumatic nerve injury, chemotherapy-induced neuropathy, and idiopathic small-fiber neuropathy each have different mechanisms and different evidence bases. Few peptides have neuropathy-specific RCTs.
Peptides with the most relevant evidence
Cerebrolysin
Porcine-derived peptide preparation with multiple RCTs in stroke recovery, vascular dementia, and traumatic brain injury. Some data in diabetic neuropathy with reported improvements in nerve conduction parameters and symptom scores. The evidence is mixed and the trials are heterogeneous in design.
BPC-157
Animal-model nerve regeneration data is consistent — sciatic nerve injury models show accelerated functional recovery, and peripheral nerve transection models show improved morphological recovery. Mechanism includes growth-factor signaling and angiogenesis-related effects.
Zero completed human trials in neuropathy. The animal-to-human translation gap is substantial here.
Semaglutide / Tirzepatide
Diabetic neuropathy is in part a consequence of chronic hyperglycemia. GLP-1 agonists improve glycemic control and have shown secondary-endpoint improvements in neuropathy symptoms in T2D trials. The effect is downstream of glycemic improvement, not direct nerve action — but for diabetic neuropathy specifically, this is a clinically meaningful pathway.
Full semaglutide profile → | Full tirzepatide profile →
Supporting cast
Selank
Anxiolytic peptide with possible neurotrophic action in animal models. Limited neuropathy-specific data.
Semax
Heptapeptide with neurotrophic and BDNF-modulating activity. Russian-research-program data; limited Western replication. Some discussion in nerve-injury contexts but neuropathy-specific RCT data is absent.
What the evidence does not support
- Use of BPC-157 as a neuropathy "cure" claim — animal data is not clinical evidence
- Use as substitute for primary treatment of underlying cause (glycemic optimization in diabetic neuropathy, treatment discontinuation in toxic neuropathy)
- Peptide use during active chemotherapy without oncology coordination
Where to source
Cerebrolysin and Russian-research peptides have limited independent vendor testing data.
What we don't know
- Whether BPC-157 produces meaningful nerve-function improvement in human peripheral neuropathy
- Optimal duration of cerebrolysin courses in chronic neuropathy
- Whether GLP-1 agonist neuropathy benefits are independent of glycemic improvement
- Cancer-relevant safety of growth-factor-modulating peptides in chemotherapy-induced neuropathy patients
Methodology
Read the full methodology.
This page is educational. Neuropathy etiology determines treatment. A neurology evaluation, EMG/NCV studies where indicated, and treatment of underlying disease are the foundation; peptide therapy is at best adjunctive.